Hospitals are buying, but the timing of delivery matters
GE HealthCare reported third-quarter revenue of $5.5 billion, a 7.2% increase, with organic growth of 6.2%. The more revealing measure for the company's industrial outlook is its $23.7 billion order backlog. Organic orders grew 4%, and book-to-bill stood at 1.03, indicating that new orders modestly exceeded the revenue recognised during the quarter. In a market where hospitals often finance expensive imaging equipment over long procurement cycles, the order pipeline can be a better guide to demand than a single quarter's shipments.
Backlog is not cash in the bank. Orders can be rescheduled, financing may be reconsidered, and equipment must be manufactured, installed and accepted before revenue is recognised under the relevant terms. A book-to-bill ratio only slightly above one also does not demonstrate an accelerating order boom. The figures instead support a measured conclusion: demand remains sufficient to replenish the company's work, even as health systems face budget and staffing pressures.
Margin expansion has more than one explanation
Net income attributable to the company rose to $615 million from $446 million, while its net income margin increased to 11.1% from 8.7%. Adjusted EBIT reached $913 million, compared with $761 million a year earlier. Management attributes the margin improvement to higher volumes, pricing, productivity and a favourable year-on-year net tariff effect, partly offset by inflation. Those components are operationally different and should not be compressed into a single claim that AI software is driving earnings.
The company reported adjusted EBIT margin of 16.6%, up from 14.8%. That is a non-GAAP measure designed to help comparison, not a substitute for statutory operating performance. The most useful test over coming quarters will be whether higher equipment utilisation, service revenue and product mix can sustain margin improvement when tariff comparisons and procurement timing change.
The $55 million that investors should not overlook
Operating cash flow was $907 million, and free cash flow, as defined by the company, was $793 million. Both figures included a $55 million tariff refund. Removing that refund mechanically would leave $738 million of free cash flow, but that simple subtraction is not a formally reported adjusted measure and does not capture every tax, working-capital or timing effect. It does show why the cash improvement should be read with care.
Capital expenditure of $114 million was close to the prior-year $110 million. The company reported $2.9 billion in cash and cash equivalents and $10 billion in outstanding debt. Its balance sheet therefore offers investment capacity, but acquisitions and dividends compete with the need to fund new products and manufacturing. A strong cash quarter is valuable precisely because this is a capital-intensive equipment and services business.
A radiopharmaceutical deal changes the strategic mix
In October the company announced plans to acquire SOFIE Biosciences for $945 million in cash, subject to approvals and other closing conditions, with completion expected in the first half of 2027. The proposed purchase is about radiopharmaceutical supply infrastructure, not simply another diagnostic scanner. It would broaden GE HealthCare's exposure to the production and distribution of agents used in advanced imaging and related treatment pathways.
The commercial rationale is plausible: medical imaging depends on an ecosystem of devices, software, isotopes, radiopharmaceuticals and trained clinical teams. But a proposed acquisition is not yet an operating contribution. Investors should ask how much integration investment will be required, how margins compare with the equipment business and whether the company can secure reliable supply and regulatory compliance. Those answers are not established by the purchase announcement.
The broader US medical-technology signal
GE HealthCare's results are an instructive counterpoint to narratives that treat healthcare investment as either uniformly constrained or uniformly booming. Hospitals can defer capital purchases while still needing productivity improvements and replacement equipment. Demand for diagnostics, monitoring and clinical workflow tools is shaped by patient volumes, reimbursement, staffing and the age of installed systems, not just headline GDP growth.
Management raised its full-year guidance, but the release itself warns that forward-looking non-GAAP measures are not fully reconciled to GAAP because of uncertain future items. The next checkpoints are order conversion, organic growth by segment, cash generation without one-offs and execution of the proposed SOFIE transaction. The quarter supports confidence in a sizeable installed-market business, while leaving open how much of the improvement will prove repeatable.